UBS upgrades Lundbeck to 'buy' on epilepsy drug conviction
UBS upgraded H Lundbeck to "buy" from "neutral", citing strong conviction in its developing epilepsy drug bexicaserin, which it forecasts could offset patent expirations for its key drug Rexulti in 2029 and achieve $2 billion in peak sales. The brokerage added that Lundbeck's strong cash generation provides firepower f